U.S. flag

An official website of the United States government

GTR Home > Tests > BRCA1 and BRCA2 gene

Laboratory contact

Laboratory information


QDx Pathology Services, Inc., QDx Pathology Services

Laboratory director(s)

  • Wissam Hamou, PhD, Lab Director
  • Veronica Mogerman, BA, Lab Associate Director
  • Shazia Nishtar, MBBS, MPhil (Clinical Chemistry), Manager, Molecular Laboratory

Laboratory contact

  • Molecular
  • Edison, New Jersey
  • United States

Laboratory affiliations

  • EMES Professional Associates, Inc.

Laboratory services offered

  • Custom Deletion/Duplication Testing

Laboratory credentials

CLIA certification

  • Number: 31D2026917, Expiration: 2023-02-03

State license(s)

  • NJ - State of New jersey Department of Health and Senior Service, License number: 0007948, Expiration: 2021-12-31
  • CA - California Department of Public Health CDPH, License number: CDS00800656, Expiration: 2022-01-26
  • NY - New York State Department of Health NYSDOH, License number: PFI9045, Expiration: 2022-06-30
  • PA - Pennsylvania Department of Health PADOH, License number: LABID36326, Expiration: 2022-08-15


  • CAP, Number: 9001384, Expiration: 2022-04-05

Suggested reading

  • USPSTF, 2019
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force
  • USPSTF, 2013
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation (See 2019 Update)
  • Phillips et al., 2013
    Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
  • Domchek et al., 2010
    Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality

Practice guidelines

  • NCCN, 2022
    NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022
  • ACMG ACT, 2019
    American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.